drugset / Trial / NCT01064037
A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute decompensated heart failure.
Timeline
- Start
- 2010-04
- Primary completion
- 2011-02
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cinaciguat | Small molecule | 50 ug | Intravenous |
| Subject | Cinaciguat | Small molecule | 100 ug | Intravenous |
| Subject | Cinaciguat | Small molecule | 150 ug | Intravenous |